Related Experiment Video

Updated: Aug 11, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

TORgeting oncogene addiction for cancer therapy

Andrew Y Choo1, John Blenis

  • 1Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Cancer Cell
|February 14, 2006
PubMed

Insights

Loss of the VHL tumor suppressor gene may predict cancer sensitivity to rapamycin therapy. This finding aids in developing targeted cancer treatments by identifying key biological markers for activated oncogenic pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The PI3K-Akt-mTOR pathway regulates cell growth and is hyperactivated in numerous cancers.
  • Rapamycin analogs, mTOR inhibitors, show promise as cancer therapeutics.
  • Tumor heterogeneity necessitates identifying biomarkers for effective targeted therapy.

Purpose of the Study:

  • To identify biological markers that determine tumor sensitivity to rapamycin therapy.
  • To investigate the role of the VHL tumor suppressor gene in cancer response to mTOR inhibition.

Main Methods:

  • Analysis of tumor genetic background.
  • Assessment of biochemical pathways involved in cancer growth.
  • Evaluation of tumor response to rapamycin treatment in relation to VHL gene status.

Main Results:

  • The study identifies the loss of the VHL tumor suppressor gene as a potential factor influencing tumor sensitivity to rapamycin.
  • This finding suggests a link between VHL gene status and the efficacy of mTOR-targeted therapy.

Conclusions:

  • Loss of VHL may serve as a predictive biomarker for rapamycin therapy in certain cancers.
  • Understanding the genetic basis of VHL loss can guide the development of personalized cancer treatments targeting the PI3K-Akt-mTOR pathway.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.